EDITORIAL

Quality of Life data in immune oncology trials: from side note to centre stage?
Despite greater attention being given to treatment effects on patient wellbeing, the high heterogeneity of methodologies still limits the usefulness of QoL assessment
ESMO GASTROINTESTINAL CANCERS CONGRESS 2025

Promising activity reported for olaparib in advanced biliary tract cancers
Study indicates that PARP inhibition could extend treatment options for patients with biliary tract cancers
Prolonged intertreatment interval improves outcomes to EGFR rechallenge in metastatic colorectal cancer
Randomised trials and real-world data propel the anti-EGFR rechallenge approach towards standard of care, but more solid evidence is needed
Atezolizumab and bevacizumab after transarterial chemoembolisation prolongs progression-free survival in unresectable hepatocellular carcinoma
Data from the TALENTACE trial add to growing evidence supporting the combination of immunotherapy plus anti-VEGF component with TACE
AI & DIGITAL ONCOLOGY

AI-driven tool shows to improve risk stratification in colorectal cancer
A system integrating computer tomography scans and pathological markers offers promise to personalise adjuvant therapy
Embracing interdisciplinary collaboration for an AI-driven oncology
ESMO now welcomes members from other disciplines to support and expedite the digital transformation of cancer care
AI is transforming cancer diagnosis, but systemic barriers still hold it back
A new ESMO systematic review maps AI’s growing role in pathology and oncology, as well as challenges in its implementation due to infrastructure, regulatory framework and human factors